The antibodies produced by the EpiVacCorona vaccine are capable of neutralizing the reference strain of the coronavirus, as well as the British and South African variants, the Vector State Scientific Center for Virology and Biotechnology, which created the drug, told TASS.
“As part of an experimental test of the effectiveness of the EpiVacCorona vaccine, it was found that the antibodies induced by the vaccine have neutralizing activity against all of these strains,” the Vector center said.
According to the results of clinical and post-registration studies of EpiVacCorona, there is no reason to doubt the safety of the vaccine and the production of neutralizing antibodies, they noted there.
The results of vaccine studies show that antibodies to coronavirus remain for 9-10 months, said Alexander Semyonov, head of the Yekaterinburg Research Institute of Viral Infections, which is part of the Vector Center for Virology and Biotechnology. Moreover, “EpiVacCorona” is suitable for revaccination, you can vaccinate “as much as you like”, he noted.
EpiVacCorona is the second COVID-19 vaccine registered in Russia. President Vladimir Putin announced its registration in October last year. According to Rospotrebnadzor, according to the results of two phases of clinical trials, the effectiveness of the vaccine was 100%. At the end of April, the Vector Center announced the production of more than 2.1 million doses of the drug.
According to Deputy Prime Minister Tatyana Golikova, new strains of coronavirus have been identified in 54 regions of Russia.
